219A Heartseed Inc.HeartseedTSE Growth / Pharmaceuticals
0 posts
Heartseed Inc. (219A) at a glance
Prices are from Yahoo! Finance and may be delayed. Always check the latest price before trading.
Heartseed Inc. (219A) Stock Price History
Heartseed Inc. closed at ¥2,590 on Nov 20, 2026, +1.8% over 1 month, +50.8% over 1 year.
If you had invested ¥100,000 1 month ago, it would be worth ¥101,768 today (+1.8%).Price change only; dividends and fees are not included.
Over the same period the Nikkei 225 moved −11.9%, while this stock moved +1.8%.
Last 10 Trading Days
| Date | Close | Change | % Change |
|---|---|---|---|
| Nov 20 (Fri) | ¥2,590 | −110 | −4.07% |
| Nov 19 (Thu) | ¥2,700 | −33 | −1.21% |
| Nov 18 (Wed) | ¥2,733 | −121 | −4.24% |
| Nov 17 (Tue) | ¥2,854 | −98 | −3.32% |
| Nov 16 (Mon) | ¥2,952 | +67 | +2.32% |
| Nov 13 (Fri) | ¥2,885 | −20 | −0.69% |
| Nov 12 (Thu) | ¥2,905 | −120 | −3.97% |
| Nov 11 (Wed) | ¥3,025 | −5 | −0.17% |
| Nov 10 (Tue) | ¥3,030 | +179 | +6.28% |
| Nov 9 (Mon) | ¥2,851 | +151 | +5.59% |
If you had invested ¥100,000 3 months ago, it would be worth ¥113,896 today (+13.9%).Price change only; dividends and fees are not included.
Over the same period the Nikkei 225 moved −14.8%, while this stock moved +13.9%.
Last 10 Trading Days
| Date | Close | Change | % Change |
|---|---|---|---|
| Nov 20 (Fri) | ¥2,590 | −110 | −4.07% |
| Nov 19 (Thu) | ¥2,700 | −33 | −1.21% |
| Nov 18 (Wed) | ¥2,733 | −121 | −4.24% |
| Nov 17 (Tue) | ¥2,854 | −98 | −3.32% |
| Nov 16 (Mon) | ¥2,952 | +67 | +2.32% |
| Nov 13 (Fri) | ¥2,885 | −20 | −0.69% |
| Nov 12 (Thu) | ¥2,905 | −120 | −3.97% |
| Nov 11 (Wed) | ¥3,025 | −5 | −0.17% |
| Nov 10 (Tue) | ¥3,030 | +179 | +6.28% |
| Nov 9 (Mon) | ¥2,851 | +151 | +5.59% |
If you had invested ¥100,000 6 months ago, it would be worth ¥170,059 today (+70.1%).Price change only; dividends and fees are not included.
Over the same period the Nikkei 225 moved −5.6%, while this stock moved +70.1%.
Monthly Closes
| Month | Month-End Close | Monthly % |
|---|---|---|
| Nov 2026 | ¥2,590 | −14.1% |
| Oct 2026 | ¥3,015 | +15.3% |
| Sep 2026 | ¥2,615 | +5.6% |
| Aug 2026 | ¥2,477 | +47.2% |
| Jul 2026 | ¥1,683 | +0.9% |
| Jun 2026 | ¥1,668 | +8.2% |
| May 2026 | ¥1,542 | −13.2% |
If you had invested ¥100,000 1 year ago, it would be worth ¥150,757 today (+50.8%).Price change only; dividends and fees are not included.
Over the same period the Nikkei 225 moved +13.3%, while this stock moved +50.8%.
Monthly Closes
| Month | Month-End Close | Monthly % |
|---|---|---|
| Nov 2026 | ¥2,590 | −14.1% |
| Oct 2026 | ¥3,015 | +15.3% |
| Sep 2026 | ¥2,615 | +5.6% |
| Aug 2026 | ¥2,477 | +47.2% |
| Jul 2026 | ¥1,683 | +0.9% |
| Jun 2026 | ¥1,668 | +8.2% |
| May 2026 | ¥1,542 | −13.2% |
| Apr 2026 | ¥1,777 | +2.7% |
| Mar 2026 | ¥1,730 | −14.7% |
| Feb 2026 | ¥2,028 | +6.6% |
| Jan 2026 | ¥1,903 | +5.5% |
| Dec 2025 | ¥1,804 | +4.6% |
| Nov 2025 | ¥1,724 | ― |
If you had invested ¥100,000 3 years ago, it would be worth ¥215,654 today (+115.7%).Price change only; dividends and fees are not included.
Over the same period the Nikkei 225 moved +57.2%, while this stock moved +115.7%.
Yearly Closes
| Year | Year-End Close | Yearly % |
|---|---|---|
| 2026 (YTD) | ¥2,590 | +43.6% |
| 2025 | ¥1,804 | ― |
Daily, weekly and monthly closes (Yahoo! Finance, split-adjusted, dividends excluded). "All" covers the range Yahoo provides (from Jul 2024). Please check the latest prices before trading.
Heartseed Inc. (219A) financial indicators
PER, ROE and dividend yield are based on company forecasts, calculated from earnings reports and the closing price after each trading day.
Key features of Heartseed Inc. (219A)
Business overview
The company is a drug discovery company aiming to establish myocardial regenerative medicine, transplanting micro-tissues of heart muscle cells made from iPS cells (cardiac spheroids) into the heart, to help patients with severe heart failure. It has a single segment. Its treatment under development in Japan falls under regenerative medicine products, and it aims to obtain conditional, time-limited approval using a system that shortens development and approval periods. It is developing several programs to broaden delivery methods and target diseases. In its lead program HS-001 (open-chest delivery of allogeneic iPS cell-derived cardiac spheroids), it is running the LAPiS trial, administering the treatment together with coronary artery bypass surgery to 10 patients with severe heart failure due to ischemic heart disease, and completed 52-week follow-up in January 2026. It is also preparing to start the EMERALD trial of catheter-delivered HS-005 in 2026.
Summarized from the annual securities report (fiscal year ended December 2025) filed on EDINET.
Position within Pharmaceuticals (79 companies)
| PBR | 8.91x | Above the sector median of 1.86x (No. 72 from the lowest) |
|---|---|---|
| ROE | -32.47% | No. 42 in the sector (highest first); median 4.17% |
| Market cap | ¥59.3 bn | No. 27 in the sector (largest first) |
Ranks among stocks in the same Tokyo Stock Exchange sector (33 sectors). PER and PBR of zero or below (losses, negative equity) are excluded and ranked from the lowest.
Price milestones
| 52-week high | ¥3,090 | 10/29 |
|---|---|---|
| 52-week low | ¥1,405 | 6/1 |
| Current position | 70.3% | Where the low is 0% and the high is 100% (close on 11/20: ¥2,590) |
| Year to date | +43.6% | No. 5 of 77 in the sector (best first) |
| 1 year | +50.8% |
Based on closing prices (adjusted for stock splits, excluding dividends).
Kabutaro's ranking history
| Top 50 gainers | 3 times | Latest: 10/28 (No. 43) |
|---|
Gainers and losers have been recorded since 9/2026.
Calculated as of 2026/11/20 17:30 JST. Updated every business day in the evening.
Recent disclosures (TDnet, in Japanese)
- 11/13 15:302026年12月期 第3四半期決算短信〔日本基準〕(非連結)
- 11/10 15:30他家iPS細胞由来心筋球「HS-001」の厚生労働省「希少疾病用再生医療等製品」対象品目指定に関するお知らせ
- 11/10 15:30他家iPS細胞由来心筋球「HS-001」の厚生労働省「先駆的再生医療等製品」対象品目指定に関するお知らせ
- 10/27 15:30心筋再生医療HS-005(カテーテル投与)の第1/2相企業治験における 虚血性心疾患群の第1例目実施に関するお知らせ
Filings from the past 12 months (4).
Posts
This board is shared with the Japanese and Chinese versions. Feel free to write in English, Chinese or Japanese.
No posts yet. Be the first to write something.